Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Inclusion Criteria: * Cytologically or histologically confirmed pancreatic adenocarcinoma (excluding islet cell or ampullary tumors) that is metastatic or unresectable * Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * Patients may have received prior chemotherapy for advanced disease as long as it did not include gemcitabine; if patients received prior adjuvant therapy including gemcitabine, patients must be \> 6 months from the last dose of gemcitabine; patients must have recovered from side effects of prior therapy to grade =\< 1 as measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0 * Patients may have received prior radiation presuming \> 4 weeks since last dose and measurable disease outside the radiation field * Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 * Anticipated life expectancy of greater than 3 months * Leukocytes \>= 3,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL * Total bilirubin \< 2.5 x institutional upper limit of normal (ULN) * Aspartate aminotransferase (AST) (serum glutamic pyruvate transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional upper limit of normal OR =\< 5 x institutional upper limit of normal when liver metastases are present * Creatinine within normal institutional limits OR creatinine clearance \>= 60 mL/min…